Sharechat Logo

AFT Pharmaceuticals gets greenlight for nine additional European countries

Friday 19th May 2017

Text too small?

AFT Pharmaceuticals obtained regulatory approval to sell its Maxigesic painkiller in nine additional European countries, a move that lets it ramp up international sales of its tablets. 

The Auckland-based drug maker said the European Medicines Agency approved Maxigesic tablets in Austria, Belgium, Croatia, France, Germany, Luxembourg, Netherlands, Portugal and Spain. These countries have been added to the existing European countries where Maxigesic has been approved for sale.

"Collectively they have over US$1.8 billion of annual sales of paracetamol and ibuprofen tablets,” said chief executive Hartley Atkinson. "So approval across most of the EU is a crucial piece of the puzzle for Maxigesic in terms of ramping up international sales and significantly reducing the regulatory risk for Maxigesic tablets."  

The EMA’s decision immediately clears the way for Maxigesic product launches in countries where AFT Pharmaceuticals already has a license agreement in place: Belgium, Luxembourg, Spain, Portugal and Ireland. It will add to existing launches in the UK, Italy and a planned launch in the Nordics. The EMA decision is expected to accelerate licensing negotiations in EU countries where agreements are not yet in place. 

"We know that for most of the EU, Maxigesic has now been approved, and so we expect to make further progress in reaching licensing agreements in those remaining EU countries in this financial year," said Atkinson. 

Earlier this month, AFT said it sold 74 million tablets in the year ended March 31, up from 22 million tablets a year earlier, it said in a statement. The company will report earnings next Wednesday and in March said it expected to generate annual sales of between $69 million and $71 million, up from $65.8 million a year earlier.

The stock last traded at $2.30 and has fallen 25 percent over the past 12 months. 

(BusinessDesk)




Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.
Bookmark and Share   Printable version
Related News

Metroglass profit dips on Aussie expansion costs, capex looms
NZ dollar climbs back above 70 US cts as Fed minutes raise question over June hike
While you were sleeping: Wall St ticks higher
MARKET CLOSE: NZ shares rise, led by Arvida as upbeat earnings buoy investors
NZ dollar slips below 70 US cents
Plant & Food Research-Anagenix tie up on the verge of reaping benefits
Air New Zealand passenger numbers rise in April
Unite Union makes headway in talks with Restaurant Brands
SSC to probe Transport Ministry's treatment of whistleblowers
FMA licenses 201 firms under new securities law regime

IRG See IRG research reports